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Stimulation of Purinergic Receptors Modulates
Chemokine Expression in Human Keratinocytes
Saveria Pastore1, Francesca Mascia1, Sara Gulinelli2, Sylvia Forchap2, Cristina Dattilo1, Elena Adinolfi2,
Giampiero Girolomoni3, Francesco Di Virgilio2 and Davide Ferrari2
ATP is abundantly released from stressed or damaged cells in response to mechanical stimulation, bacteria, or
noxious agents. In this study, we have investigated the possible involvement of P2 receptors (receptor for
extracellular nucleotides) in the expression and release of inflammatory mediators by human keratinocytes.
Notably, extracellular ATP displayed a complex regulation of IFN-g-stimulated chemokine expression, with
upregulation of CC chemokine ligand 2 (CCL2), CCL5 and CXC chemokine ligand 8 (CXCL8), and suppression of
the receptor CXC chemokine receptor 3 (CXCR3), CXCL9, CXCL10, and CXCL11. The effect of ATP was mimicked
by ADP and adenosine-50-O-3-thiotriphosphate, whereas 20,30-O-(4-benzoylbenzoyl) ATP (BzATP) down-
modulated all chemokines investigated. UTP had no effect on IFN-g-stimulated chemokine secretion. The
broad-spectrum P2 receptor antagonist suramin and the selective P2Y1 inhibitor adenosine 3
0-phosphate
50-phosphosulfate counteracted the effect of ATP on secretion of all the chemokines examined, whereas
pyridoxal phosphate 6-azophenyl 20,40-disulfonic acid and KN62 (1-[N,O-bis(5-isoquinoline sulfonyl)-N-methyl-L-
tyrosyl] 4 phenylpiperazine) partially prevented the inhibitory effect of ATP on CXCL10 secretion, but on the
other hand potentiated the ATP-stimulatory effect on CCL5, CCL2, and CXCL8 release. In lesional skin of
psoriasis and atopic dermatitis patients, intense P2X7 reactivity was confined to the cell membrane of the basal
layer, whereas diffuse P2Y1 immunostaining was found throughout the epidermis. Collectively, our data suggest
that the orchestrated activation of distinct P2Y and P2X receptors modulates skin inflammation.
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INTRODUCTION
The skin is a highly specific immune defense organ. Physical,
chemical, or immune-specific insults rapidly evoke the
response of resident cells of the epidermis, characterized by
the increased expression of a wide range of proinflammatory
mediators. In particular, keratinocytes can release high
amounts of (CC ligand), chemokine of the CC subfamily
(CCL)2/monocyte chemoattractant protein-1 and CCL5/
RANTES (regulated upon activation, normal T cell expressed
and secreted), active in the recruitment of monocytes/
macrophages, dendritic cells and T cells, and (CXC ligand),
chemokine of the CXC subfamily (CXCL)8/IL-8, a selective
neutrophil chemoattractant (Pastore et al., 2004). Type 1
T helper (Th1) cells, crucial effectors in chronic inflammatory
skin disorders, are attracted into the skin by the release of
CXCR3 ligands, namely CXCL9/monokine-induced by IFN-g
(MIG), CXCL10/IFN-g-induced protein of 10 kDa (IP-10),
CXCL11/IFN-g-induced T cell a chemoattractant (ITAC). The
expression of these chemokines is strongly upregulated by
IFN-g, abundantly released by Th1 cells (Albanesi et al.,
2005).
Growing evidence suggests that ATP is not only a source
of energy for the cell but also an important intercellular
mediator in both physiological and pathological conditions.
In particular, extracellular nucleotides may act as early
danger signals, alerting immune cells of tissue injury or stress.
In response to mechanical stimulation, bacterial infections or
cell damage, ATP, and other nucleotides including ADP and
UTP may be released into the extracellular space (Ferrari
et al., 1997; Pellegatti et al., 2005), and once released, they
activate a family of plasma membrane receptors known
as purinergic (P2) receptors (receptor for extracellular
nucleotides). ATP and UTP can be released via lytic or
non-lytic mechanisms involving vesicle-mediated secretion,
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carrier-mediated transport, or plasma membrane channels
(Filippini et al., 1990; Jiang et al., 1998; Dixon et al., 1999;
Burrell et al., 2005). P2 receptors can be classified according
to the molecular structure into two subfamilies, P2Y and P2X
(Dubyak and el-Moatassim 1993; Abbracchio and Burnstock,
1994). P2Y receptors are seven-membrane-spanning proteins
(Von Kugelgen and Wetter, 2000). To date, eight P2Y
subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13,
and P2Y14) have been cloned. P2X receptors are cation-
selective, ligand-gated channels (North, 2002). Seven P2X
receptor subtypes have been cloned so far (P2X1–7). P2X
subunits aggregate to form homomeric or heteromeric
channels.
A number of experimental observations indicate that ATP
may play a relevant role in skin inflammation (Holzer and
Granstein, 2004). However, the detailed characterization of
its effects on keratinocyte proinflammatory activation is still
missing. In this study, we demonstrate that ATP affects
chemokine expression in cultured normal human keratino-
cytes with a relevant, dose-dependent downregulation of
CXCR3 ligands and upregulation of CCL2, CCL5, and CXCL8.
In keeping with previous evidence, we found that human
keratinocytes express P2Y and P2X receptor subtypes (Burrell
et al., 2003; Greig et al., 2003b; Inoue et al., 2005), and their
stimulation is coupled to [Ca2þ ]i transients (Pillai and Bikle,
1992; Dixon et al., 1999; Burrell et al., 2003). Of note, only
P2X7 and P2Y1 were found upregulated by IFN-g. Chronic
lesions from psoriasis and atopic dermatitis patients stained
intensely with specific anti-P2X7 and anti-P2Y1 antisera.
These data emphasize the multifaceted roles of extracellular
adenine nucleotides during skin inflammation.
RESULTS
Adenine nucleotides differentially affect expression
of proinflammatory mediators in keratinocytes
ATP is a potent cytotoxic effector in several cell types (Di
Virgilio et al., 1998). In monocyte-derived dendritic cells,
90 minutes incubation in the presence of 1 mM ATP causes
cytolysis of over 20% of the cell population (Ferrari et al.,
2000). In contrast, adherent human keratinocytes were much
more resistant to ATP-triggered cytotoxicity. Following
24 hours incubation in the presence of 1 mM ATP, 20,30-O-
(4-benzoylbenzoyl) ATP (BzATP), adenosine-50-O-3-thiotri-
phosphate (ATPgS), or UTP, only 2–5% of the cells were
killed (Figure 1). The addition of IFN-g or tumor necrosis
factor-alpha (TNF-a) together with ATP did not affect this
striking insensitivity to nucleotide-mediated cytotoxicity (not
shown). Chronic incubation in the presence of low concen-
trations of ATP reduced the intracellular accumulation of
IL-1a and IL-1b, but not IL-1ra, either in the presence or
absence of IFN-g or TNF-a (Figure S1, Supplementary
Material). ATP had no effect on the very low extracellular
levels of these cytokines (data not shown). These data
suggested that chronic ATP signalling downmodulated the pro-
inflammatory function of epidermal keratinocytes. To further
investigate this hypothesis, we examined the effects of nucleo-
tide signalling on the expression of a cluster of chemokines
including the CXCR3 ligands, CCL2, CCL5, and CXCL8.
Chronic exposure to ATP dose-dependently downregulated
IFN-g-induced release of CXCR3 ligands (Figure 2a) and
downmodulated their mRNA levels, as shown by real-time
reverse transcriptase (RT)-PCR (Figure 2b–d). In contrast, ATP
stimulated CCL5 and CXCL8 mRNA levels at the longest time
point tested (16 hours) (Figure 3a). The CCL2 transcript was
also upregulated by ATP at 4 and 8 hours time points.
Downmodulation of CXCL10 gene expression by ATP is also
shown for comparison. Dose-dependency curves of nucleo-
tide-dependent modulation of IFN-g-driven chemokine
secretion showed that maximal effect was reached at about
500mM ATP, and that ADP was also effective. ATPgS was a
more potent inducer of CCL5 and CXCL8 release than ATP,
whereas BzATP had a generalized inhibitory activity and UTP
lacked any effect whatsoever (Figure 3b–e). Neither ATP nor
ADP or ATP synthetic analogs significantly affected TNF-
a-induced chemokine expression or release (data not shown).
P2 receptor expression in human keratinocytes
Many responses elicited by extracellular nucleotides are
mediated by an increase in the intracellular Ca2þ concentra-
tion ([Ca2þ ]i), thus we investigated Ca
2þ signalling in
nucleotide-stimulated keratinocytes. Human keratinocyte
monolayers were loaded with the fluorescent Ca2þ indicator
fura-2/AM, and intracellular Ca2þ changes were monitored
by fluorometric analysis. In the presence of extracellular
Ca2þ , ATP (1 mM) triggered a fast [Ca2þ ]i increase followed
by a sustained plateau (Figure 4a, continuous line). ATP
threshold concentration for the [Ca2þ ]i rise was 30 nM, while
plateau was reached at 30mM (Figure 4b). At the concentra-
tion of 30 nM, ATP caused a slow and long-lasting increase in
the [Ca2þ ]i (Figure 4a, dashed line). In the absence of
extracellular Ca2þ , ATP triggered a spiking increase in
[Ca2þ ]i, which was not followed by a sustained plateau
(Figure 4c, continuous line). Under these conditions, the ATP
threshold was shifted to 300 nM, while ATP concentration for
plateau was 100mM (see Figure 4d and c, dashed line). The
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Figure 1. Lack of cytotoxic effect of P2 agonists in human keratinocytes.
Keratinocyte cultures were incubated with increasing nucleotide
concentrations and their medium was collected for lactic dehydrogenase
analysis after 24 hours. Data were normalized per 106 cells and are
expressed as means7SD of triplicate determinations.
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P2Y2 and P2Y4 agonist UTP was also a potent stimulus for
[Ca2þ ]i increase (Figure 4e and f). Figure 4f shows UTP dose-
dependency curve; the most effective concentration for the
[Ca2þ ]i rise was about 1 mM UTP. BzATP induced a spiking
[Ca2þ ]i increase both in the presence or absence of
extracellular Ca2þ (Figure 4g). Figure 4h shows the dose-
dependency curve in keratinocytes stimulated with BzATP in
the presence of external Ca2þ . ADP and ATPgS were also
potent stimuli for [Ca2þ ]i increases in keratinocytes (not
shown). No response to UTP-glucose was observed. The wide
range of nucleotides acting as Ca2þ -mobilizing agonists
indicated expression of multiple P2Y receptors, among which
are P2Y2 and P2Y4 (activated by UTP), P2Y1, P2Y12 and
P2Y13 (activated by ADP), and P2Y11 (activated by BzATP
and ATPgS). Indeed, the specific transcripts for P2X1, P2X3,
P2X4, P2X5, P2X6, and P2X7 subtypes, and P2Y1, P2Y2, P2Y4,
P2Y6, P2Y11, P2Y12, and P2Y13 subtypes, but not P2Y14 (not
shown), were detected by RT-PCR (Figure S2, Supplementary
Material). Among P2 receptors subtypes, only P2X7 and P2Y1
were reproducibly upregulated by IFN-g, whereas TNF-a
downregulated P2X7 at 6 h time point (Figure 5).
Differential contribution of P2 receptors to chemokine
expression
To identify the P2 receptor subtypes responsible for nucleo-
tide-dependent modulation of IFN-g chemokine release,
we tested several P2 blockers. Suramin was used as a
700
600
500
400
300
200
100
G
en
e 
ex
pr
es
sio
n 
(r.u
.)
G
en
e 
ex
pr
es
sio
n 
(r.u
.)
G
en
e 
ex
pr
es
sio
n 
(r.u
.)
500
400
300
200
100
2000
1500
1000
500
400
300
200
100
Time (hours)
IFN-
50  M ATP
−
− − − − −
−
0
2
+ + + +
++++++++
4 8 16 2 4 8 16
0
0
0 2 10
Concentration ATP ( M)
50 250 500
CXCL9
CXCL10
CXCL11
CXCL9
CXCL10
CXCL11
****
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
n
g /
10
6  
ce
lls
a
b
c
d
Figure 2. ATP dose-dependently downregulates CXCR3 ligands.
(a) Chemokines were measured in cell supernatants after 24 hours
co-treatment with IFN-g and increasing doses of ATP. Results are expressed as
the mean of three independent experiments7SD. For the three curves,
*Po0.05 and **Po0.01 versus culture condition in the absence of ATP.
(b–d) Time course of CXCR3 ligands transcript levels as obtained by SYBR
Green-based quantitative real-time RT-PCR. Data are representative of
four independent experiments. *Po0.01 versus culture conditions in the
absence of ATP at the same time point.
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Figure 3. ATP increases CCL2, CCL5, and CXCL8 expression in
keratinocytes. (a) Chemokine gene expression was measured by RNase
Protection Assay in total RNA (10mg) extracted from keratinocytes stimulated
with IFN-g with or without 50 mM ATP for the time points indicated.
(b–e) ELISA of IFN-g-induced chemokine levels after 24 hours co-treatment
with escalating doses of ATP, UTP, or the ATP synthetic analogs ATPgS
and BzATP. Results are expressed as mean7SD of three independent
experiments.
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wide-spectrum P2 antagonist (Ishii-Watabe et al., 2000),
pyridoxal phosphate 6-azophenyl 20,40-disulfonic acid (PPADS)
as a blocker, although not specific of the P2X receptors
(Denda et al., 2002; Inoue et al., 2005), KN62 (1-[N,O-bis(5-
isoquinoline sulfonyl)-N-methyl-L-tyrosyl] 4 phenylpipera-
zine) as a potent and selective P2X7 antagonist (Gargett and
Wiley, 1997; Di Virgilio et al., 2001; Idzko et al., 2003), and
adenosine 30-phosphate 50-phosphosulfate (A3P5PS) as a
selective P2Y1 antagonist (Hibell et al., 2001). For each
blocker, the following concentrations were tested: 50 and
100mM suramin, 50 and 100mM PPADS, 25 and 50 nM KN62,
and 50 and 100 mM A3P5PS with very similar results; thus
only data obtained with the higher concentrations are shown.
Chemokine secretion was affected by these antagonists
whether in the absence or presence of extracellular ATP. In
the absence of added ATP, the most relevant effect was
observed on CCL5, CCL2, and CXCL8 release that was
significantly reduced by suramin or A3P5PS (Figure 6b–d, left
panels). PPADS and KN62 had no effect on the release of
these chemokines. All the blockers caused a slight upregula-
tion of IFN-g-driven CXCL10 release that, however, was not
statistically significant (Figure 6a, left panel). In the presence
of added ATP, all the antagonists markedly influenced
chemokine expression. ATP-dependent downregulation of
CXCL10 expression was strongly counteracted by suramin
and much less so by the other antagonists (Figure 6a, right
panel). Suramin also strongly inhibited ATP-mediated stimu-
lation of CCL5, CCL2, and CXCL8 secretion (Figure 6b–d,
right panels). A3P5PS was also effective in reducing the
production of these chemokines, whereas PPADS and KN62
further enhanced ATP-dependent secretion.
P2X7 and P2Y1 upregulation in the lesional skin of atopic
dermatitis and psoriasis
The observation that extracellular nucleotides modulate IFN-
g-stimulated chemokine secretion and that P2Y1 and P2X7
expression is stimulated by IFN-g treatment prompted us to
investigate their possible involvement in skin inflammation.
At variance with previous results obtained with fluorescence-
based immunodetection (Greig et al., 2003a, b), chromogen-
based immunohistochemistry did not allow to detect P2X7 or
P2Y1 in normal human skin (Figure 7a and e). By contrast,
strong P2X7 immunoreactivity was detected in the epidermal
basal layer of chronically inflamed skin from patients with
atopic dermatitis (Figure 7b) and psoriasis (Figure 7c), with
selective localization on keratinocyte membrane. Weak,
specific membrane P2X7 staining could also be clearly
observed throughout the epidermis in atopic dermatitis
(Figure 7b). A control run with an isotype-matched Ig as
primary antibody confirmed staining specificity (Figure 7d).
In skin lesions from atopic dermatitis and psoriasis, we also
detected a diffuse reactivity using a selective anti-P2Y1
antibody, with a peri/nuclear localization particularly evident
in the suprabasal keratinocytes of atopic dermatitis lesions
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Figure 4. Extracellular nucleotides induce [Ca2þ ]i increase in human
keratinocytes. Cells were seeded onto glass coverslips, loaded with the Ca2þ
indicator fura-2/AM as reported in Materials and Methods, and stimulated
with (a–d) ATP; (e, f) UTP, or (g, h) BzATP. In panels a–d, 1 mM ATP,
continuous line; 30 nM ATP dashed line. In panel e, 1 mM UTP, continuous
line; 30 nM UTP, dashed line. In panel g, 300 mM BzATP, in the presence of
extracellular Ca2þ , continuous line; in the absence of extracellular Ca2þ ,
dashed line. Panels a, b, e, and f, presence of extracellular Ca2þ . Panels c and
d, absence of extracellular Ca2þ . For Ca2þ -free conditions, 0.5 mM EGTA
was added to Ca2þ free saline solution to chelate contaminating Ca2þ .
(b, d) ATP, (f) UTP, and (h) BzATP dose-dependency curves. Data are
meansþ SD of four independent experiments.
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Figure 5. IFN-c upregulates P2X7 and P2Y1 mRNA expression. Keratinocytes
were collected, lysed, and mRNA extracted and amplified as described in
Materials and Methods. b-Actin mRNA (Act.) was used as an internal control.
Representative RT-PCRs are shown. Samples obtained from three different
keratinocyte donors gave very similar results.
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(Figure 7f and g). Preadsorption, with the epitope against
which the anti-P2Y1 antibody was specifically raised,
abrogated tissue staining (Figure 7h).
DISCUSSION
Keratinocytes are the dominant cell population of the skin
and the major contributors to the establishment of the local
cytokine and chemokine milieu during skin inflammatory
responses (Grone, 2002; Pastore et al., 2004). In this study,
we investigated the potential role of P2 receptors in the
modulation of chemokine production in human keratino-
cytes. Of note, ATP, but not UTP, dose-dependently down-
regulated the expression of IFN-g-driven CXCR3 ligands
CXCL9, CXCL10, and CXCL11 both at the mRNA and protein
level. ATP also caused upregulation of IFN-g-driven secretion
of CCL2, CCL5, and CXCL8. ADP and the non-hydrolysable
synthetic ATP analog ATPgS mimicked ATP in its differential
effect on chemokine expression by causing downregulation
of CXCL10 and enhanced expression of CCL5, CCL2, and
CXCL8. By contrast, the synthetic nucleotide BzATP, well
known as a potent, although not selective, agonist at P2X7 (Di
Virgilio et al., 2001) displayed a distinct activity profile,
characterized by downregulation of all the chemokines
investigated.
In keeping with previous evidence, we found that human
keratinocytes expressed all P2X and P2Y receptor subtypes so
far cloned, except P2Y14 (Burrell et al., 2003; Greig et al.,
2003b; Inoue et al., 2005), and that their stimulation was
coupled to [Ca2þ ]i transients, as expected (Pillai and Bikle,
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Figure 6. Purinergic antagonists display differential effects on IFN-c-induced
chemokine expression in keratinocytes. (a–d) Cells were treated with the
indicated doses of P2 antagonists for 1 hour before the addition of IFN-g,
either in the presence or absence of ATP. Cell supernatants were then
collected after 24 hours and chemokine secretion measured by ELISA.
Data are means7SD of triplicates. *Po0.05 and **Po0.01 versus the
corresponding culture condition in the absence of antagonists.
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Figure 7. P2X7 and P2Y1 are overexpressed in chronically inflamed skin of
patients with psoriasis or atopic dermatitis. (a and e) P2 receptor expression
in the epidermis of a healthy donor (CT), (b and f) in lesional skin of atopic
dermatitis (AD) , and (c and g) chronic plaque psoriasis (PS). (d) As staining
specificity control, skin sections from patients with AD were incubated
with an isotype-matched antibody in the place of monoclonal anti-P2X7
antibody. (h) Anti-P2Y1 antibody was pre-adsorbed with the corresponding
antigen before staining of atopic dermatitis sections. Representative
immunohistochemistry pictures obtained from four healthy donors, four
patients with AD and four patients with psoriasis are shown. (a–d) P2X7,
(e–h) P2Y1. Original magnification,  200. Bar¼ 40mm.
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1992; Dixon et al., 1999; Burrell et al., 2003). However, only
P2X7 and P2Y1 were upregulated by IFN-g, suggesting a
possible involvement in keratinocyte responses to this
cytokine. In the past decade, several reports have highlighted
the involvement of P2 receptors, especially P2Y1 and P2X7, in
keratinocytes survival and proliferation (Cook et al., 1995;
Groschel-Stewart et al., 1999). In particular, Greig et al.
(2003a, b) showed that P2Y1 receptors colocalize with the
proliferation marker Ki-67 in a sub-population of basal and
para-basal keratinocytes in human adult and fetal epidermis.
Colocalization of P2Y2 and the proliferation marker prolifer-
ating cell nuclear antigen was also observed, suggesting that
these two P2Y receptors might participate in keratinocyte
proliferation. On the other hand, P2X5 and P2X7 were
colocalized with cytokeratin K10 (a differentiation marker)
and TUNEL-positive (apoptotic) cells, respectively, suggesting
a role for P2X5 and P2X7 in keratinocyte differentiation and
apoptosis. A recent report by Georgiou and collaborators
showed that P2X7 activation in monocyte-derived dendritic
cells, Langerhans cells, and keratinocytes induced permea-
bilization of plasma membrane to fluorescent cations such as
ethidium or propidium (Georgiou et al., 2005). In our hands,
ATP or BzATP did not show cytotoxicity on adherent
keratinocytes, and this held true also in the simultaneous
presence of IFN-g.
Inhibitor studies suggest a complex interplay between P2X
and P2Y receptors in the modulation of IFN-g-driven
chemokine secretion. The wide range, but poorly selective,
P2 blocker suramin abrogated all ATP-mediated effects on
chemokine secretion, and also showed an effect in the
absence of ATP treatment, especially on CCL5, CCL2, and
CXCL8. The wide range P2X antagonist PPADS partially
abrogated ATP-dependent downregulation of CXCL10, while
it enhanced the expression of CCL5, CCL2, and CXCL8. This
suggests that P2X stimulation may have a generalized
inhibitory effect on chemokine release, and that this
inhibition is released when the P2X receptors are blocked.
This interpretation is supported by the similar effect of KN62,
which, like PPADS, increased IFN-g-stimulated chemokine
secretion in the presence of ATP. Although inhibitor studies
do not allow to identify the P2X receptor involved, the finding
that the potent P2X7 agonist BzATP was the only nucleotide
that invariably downregulated these chemokines support a
role for P2X7 in the ATP-dependent inhibition of chemokine
release. The P2Y1-selective antagonist A3P5PS partially
relieved ATP-mediated suppression of CXCL10, and caused
a large reduction of ATP-stimulated potentiation of IFN-g-
driven CCL5, CCL2, and CXCL8 secretion. These results point
to P2Y1 as the main P2 receptor responsible for ATP-
mediated potentiation of CCL5, CCL2, and CXCL8 release.
This conclusion is also supported by the pharmacological
profile of nucleotide-specific effects on keratinocyte response
IFN-g stimulation. Indeed, ATP effects were fully mimicked
only by ADP (equipotent as ATP at P2Y1, P2Y12, and P2Y13)
and ATPgS (a potent agonist at P2Y1). In contrast, UTP was
inactive (thus ruling out P2Y2, P2Y4, and P2Y6) and BzATP (a
potent agonist at P2X receptors and at the P2Y11) caused a
generalized inhibition.
The complex modulation of skin inflammation in vivo is
epitomized by a report on mice deficient in CD39, the main
ecto-ATPase of Langerhans cells (Mizumoto et al., 2002). The
exaggerated acute inflammatory response to irritant agents
observed in CD39/ mice was taken as the evidence that
accumulation of ATP and/or ADP released by damaged
keratinocytes in the epidermis acted as a proinflammatory
stimulus. In keeping with this hypothesis, injection of ATP
into mouse ears triggered inflammation. In contrast, the
induction of hapten-specific contact hypersensitivity was
severely decreased in CD39-deficient mice, indicating that
endogenously released ATP might be involved in the down-
regulation of Th1 cell recruitment and/or activation. The in
vitro demonstration that chronic exposure to low ATP doses
suppresses DC-driven Th1 activation and downregulates
CXCR3 ligands both in DCs and in keratinocytes (la Sala
et al., 2003 and present data) provides a mechanism for these
in vivo observations. By contrast, a clearcut proinflammatory
role was recently proposed for purinergic agonism in the skin,
with intradermal administration of ATPgS resulting in
enhanced activation of antigen-presenting cell functions
(Granstein et al., 2005). Quite similarly to what we observed
in keratinocytes, ATPgS was shown to enhance the produc-
tion of a number of proinflammatory mediators, including
CCL2 and CXCL8, by human dermal endothelial cells (Seiffert
et al., 2006). Both suramin and PPADS effectively opposed
chemokine expression by endothelial cells, with suramin
much more effective than PPADS. These authors proposed
that P2Y11, strongly activated by ATPgS and effectively
antagonized by suramin, could be among the P2 receptors
critically implicated in the enhanced expression of pro-
inflammatory mediators by endothelial cells (Seiffert et al.,
2006).
Finally, participation of P2Y1 and P2X7 to inflammation in
the skin is also supported by the finding that they are the
only P2 receptors upregulated by IFN-g and that immuno-
reactivity for these receptors was enhanced in the lesional
skin of patients with psoriasis and atopic dermatitis. Strong
P2X7 staining was localized at the membrane of all
basal keratinocyte layers, which are actively proliferating in
these disorders, whereas P2Y1 was found throughout the
epidermis. While the real contribution of P2 receptors
to skin inflammation and/or hyperproliferation awaits
future confirmation by in vivo experiments, our data
suggest that P2 receptors play an important role in skin
inflammation.
MATERIALS AND METHODS
Subjects
Four-mm punch biopsies were taken from lesional skin of adult
patients with atopic dermatitis (n¼ 4, two females and two males,
age 25–40 years), chronic plaque psoriasis (n¼ 4, two females and
two males, age 35–45 years), and from normal skin of healthy
subjects (n¼ 4, two females and two males, age 30–45 years). None
of the patients had received oral corticosteroids within 1 month of
skin explant, and topical corticosteroids were not allowed for a
period of at least 2 weeks before enrollment. Epidermal sheets for
keratinocyte cultures were obtained from healthy individuals
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undergoing plastic surgery (n¼ 4, two females and two males; age
25–45 years). These studies were conducted according to the
Declaration of Helsinki Principles and approved by the review
board of the Istituto Dermopatico dell’Immacolata. All subjects gave
written informed consent before enrollment.
Reagents and cytokines
ADP, ATP, and UTP were from Roche (Milan, Italy). ATPgS, BzATP ,
PPADS, KN62, suramin, and A3P5PS were from Sigma Chemicals
(Milan, Italy). Fura-2/AM was from Molecular Probes (Leiden, The
Netherlands). Recombinant human TNF-a and IFN-g were from R&D
Systems (Abingdon, UK).
Keratinocyte cultures and treatments
Primary cultures were established as described (Pastore et al., 1997).
Keratinocytes were sub-cultured in serum-free medium Keratinocyte
Growth Medium (Cambrex, San Diego, CA), prepared from the
essential solution supplemented with 10 ng/ml EGF, 0.4 mg/ml
hydrocortisone, 5mg/ml insulin, 2 ml bovine pituitary extract, and
antibiotics. Second- or third-passage keratinocytes were used in all
experiments. Cultures at 80% confluence were treated with 100 ng/
ml TNF-a or 100 U/ml IFN-g alone, or together with a P2 agonist. In
some experiments, keratinocytes were pretreated with P2 antagonists
for 1 hour before stimulation with IFN-g with or without ATP. All
experiments were repeated with keratinocytes from at least three
different donors.
Lactic dehydrogenase assay
Lactic dehydrogenase activity was measured with a commercial kit
from Roche Diagnostics (Mannheim, Germany). Briefly, keratino-
cytes (2.5 105) were plated in six-well plates until they reached
subconfluence. They were subsequently incubated in the presence
of known concentrations of nucleotides, with or without IFN-g, for a
period of 24 hours. Supernatants obtained from keratinocyte cultures
that underwent total cell lysis with 0.1% Triton X-100 provided
100% of lactic dehydrogenase activity.
ELISA
Cytokines and chemokines were measured in total cell extracts
and/or supernatants with dedicated kits from BD Biosciences (San
Diego, CA).
Chemokine mRNA determination by RNase protection assay
Total RNA was extracted from keratinocytes using the TRIzol
Reagent, according to the manufacturer’s instructions (Invitrogen
SRL, Carlsbad, CA). The templates of the human chemokines, the
housekeeping molecule L32, and the RNase Protection Assay kit
were purchased from BD Biosciences.
Chemokine mRNA determination by quantitative real-time
RT-PCR analysis
Total RNA was treated with DNase I (Qiagen, Valencia, CA)
to eliminate DNA traces. cDNA was prepared by reverse transcrip-
tion of 1 mg total RNA. The primers used to detect the expression
levels of CXCL9/MIG, CXCL10, and CXCL11/ITAC transcripts
(Table S1, Supplementary Material) were designed with ABI PRISM
Primer Express 2.0 software (Applied Biosystems, Foster City, CA)
and synthesized at MWG (Milan, Italy). Continuous quantitative
measurement of the PCR products was achieved by incorporation of
SYBR Green fluorescent dye (Applied Biosystems), using the
ABI PRISM 7000 sequence detection system (Applied Biosystems).
The transcript level of each gene was normalized to the correspond-
ing b-actin.
RT-PCR of P2 receptors
Two hundred nanograms of total RNA were reverse transcribed. RT-
PCR reaction was performed to amplify both P2Y and P2X receptor
subtypes, whereas the amplification of b-actin was carried out as an
internal positive control. The specific primers used for RT-PCR
amplification were purchased from M-Medical (Milan, Italy), and
their sequence and annealing conditions can be found in Table S2,
Supplementary Material. The conditions for PCR amplification were
30 cycles, with denaturation at 951C for 45 seconds and final
extension was at 721C for 30 seconds. The PCR products were
separated in a 2% agarose gel and visualized by ethidium bromide
staining.
Cytosolic Ca2þ concentration measurements
Keratinocytes were seeded onto glass coverslips. After 24–48 hours,
cells were loaded with the Ca2þ indicator fura-2/AM (2 mM) for
20 minutes at 371C in a saline solution (125 mM NaCl, 5 mM KCl,
1 mM MgSO4, 1 mM NaH2PO4, 20 mM HEPES, 5.5 mM glucose, 5 mM
NaHCO3, 1 mM CaCl2, and 250 mM sulfinpyrazone, pH 7.4). Cover-
slips were mounted in a temperature-controlled magnetically stirred
cuvette at 371C. Fluorescence was measured with a Perkin-Elmer
fluorometer (Perkin-Elmer Ltd., Beaconsfield, UK). The excitation
was at 340–380 nm, and emission at 510 nm. Ca2þ concentra-
tion was calculated using the FLwinlab software (Perkin-Elmer)
(Grynkiewicz et al., 1985).
Immunohistochemistry
Four-mm cryostatic sections were fixed with 4% paraformaldehyde
for 10 minutes, treated with 0.3% hydrogen peroxide, permeabilized
with 0.05% Triton X-100, and then incubated for 1 hour at room
temperature with the primary antibody. Anti-human P2X7 receptor
monoclonal antibody (1.15 mg/ml) was a kind gift from Dr Gary
Buell, and was finally used 100-fold diluted. As negative controls,
anti-P2X7 antibody was omitted or replaced with isotype-matched Ig
(IgG2b). Polyclonal anti-P2Y1 antibody (0.6 mg/ml) including its
control antigen was obtained from Alomone Laboratories (Jerusalem,
Israel), and was finally used at a 80-fold dilution. For control of P2Y1
specificity, preadsorption with the corresponding peptide was
performed per the data sheet instruction. Secondary biotinylated
antibodies and staining kits were from Vector Laboratories
(Burlingame Laboratories, CA). Immunoreactivity was revealed
using avidin–biotin–peroxidase system and 3-amino-9-ethylcarba-
zole as chromogen. Sections were counterstained with Mayer’s
hematoxylin.
Statistical analysis
The Wilcoxon signed-rank test was applied to compare differences
between groups of data. Significance was assumed as a P-value of
0.05 or less.
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